Zero2IPO Ventures
VC Fund
Beijing, China
Zero2IPO Ventures is a VC fund in Beijing focused on E-Commerce and Internet. Zero2IPO Ventures is the venture investment arm under Zero2IPO Group targeted at high-potential, high-growth China enterprises. Leveraging Zero2IPO's vast network in China, Zero2IPO Ventures does not compete with other venture funds, but rather pursue a two-prong investment strategy, i.e. to co-invest with active venture capital firms ingrowth and late stage companies and to lead or co-lead in early stage startups in China. The industry focus includes Internet, mobile and wireless applications, digital media, healthcare, green-tech, consumable products and services, as well as other emerging sectors. We intend to leverage the extensive network that has been created by Zero2IPO Group, a leading venture capital and private equity market research and financial advisory company, to seek out potential investment opportunities and provide a strong value-add to our portfolio companies. Through its venture capital and private equity surveys, investment forums, training programs, and investment advisory services, Zero2IPO Group has developed a strong reputation in the China market for helping entrepreneurs connect with investors.
- Total investments:
- 88
- Last investment:
- Lead investor:
- 15%
- Fund size:
- $40M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Zero2IPO Ventures invests in
Stages Zero2IPO Ventures invests in
Countries Zero2IPO Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Angel
- $142k–$1.6M
- Series A
- $1.4M–$29M
- Series B
- $2.9M–$42M
Investment Focus
Industry
- E-Commerce 13 (15%)
- Internet 9 (10%)
- Education 8 (9%)
- Health Care 7 (8%)
- Mobile 5 (6%)
Stage
- Series A 37 (42%)
- Series B 17 (19%)
- Angel 15 (17%)
- Seed 6 (7%)
- Series C 4 (5%)
Country
- China 71 (81%)
- Taiwan 2 (2%)
- India 1 (1%)
- Indonesia 1 (1%)
- Switzerland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Danny Chung
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Gavin Ni
Founder,Chairman & CEO
|
Founder,Chairman & CEO | Total investments: 0 | Find email | |
Hubert Yuan1
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Jim Wang
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Suqiang Feng
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Guangxiang Technology
|
Guangxiang Technology is dedicated to empowering industrial scenarios through embodied intelligence technology. The company has developed a general-purpose embodied intelligence development platform, centered around its core GOPS platform, to drive innovation and intelligent transformation in industrial applications. | Seed / Jul 04, 2026 | |
Makera
|
Makera is essentially creating a maker's dream CNC machine; we use it every day for various projects and enjoy the experience, and we hope you will too. | $14.7M / Series A / May 06, 2026 | |
Xuntu Technology
|
Xuntu Technology is a leading data intelligence provider specializing in investment research and decision-making solutions. | $29M / Series A / Mar 26, 2026 | |
Ruidong New Energy
|
Ruidong New Energy provides power systems for new energy and electric vehicles. The company specializes in the design and manufacture of power systems for new energy and energy-efficient automobiles. | Series A / Dec 01, 2025 | |
Forvision
|
Forvision focuses on low-speed autonomous driving and is committed to implementing the most advanced intelligent driving technologies. | Series A / Apr 11, 2025 | |
HanchorBio
|
HanchorBio is a Biotechnology Research firm that is working to revolutionize the treatment of people with cancer. | $20M / Series A / Aug 25, 2022 | |
AlpsenTek
|
AlpsenTek is a company engaged in the research and development of machine vision sensors and algorithms. | $28.6M / Series A / Jun 06, 2022 | |
Reistone Biopharma
|
Reistone Biopharma is a clinical stage biopharmaceutical company. It is focused on rapidly developing innovative medicines through global collaborations within Research and Development | $100M / Series A / May 09, 2022 | |
Pleryon Therapeutics
|
Pleryon is a drug delivery platform company dedicated to improving the standard of living across the global community by developing programs utilizing advanced drug delivery technologies. Pleryon's platform is supported by pillar technologies and covers a broad spectrum of molecules and therapeutic areas. | $15.7M / Seed / Apr 01, 2022 | |
Ke Ning Bio
|
Ke Ning Bio is an innovative ophthalmic pharmaceutical manufacturer dedicated to developing ophthalmic drugs. | $15.7M / Seed / Apr 01, 2022 | |
| See all 88 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Zero2IPO Ventures invest in?
Zero2IPO Ventures invests primarily in E-Commerce, Internet and Education startups, most often at Series A and Series B stage. Most of the 88 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Zero2IPO Ventures's check size?
Zero2IPO Ventures typically joins rounds of $142k–$1.6M at Angel, $1.4M–$29M at Series A and $2.9M–$42M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Zero2IPO Ventures participates in.
How do I contact Zero2IPO Ventures?
Public channels for Zero2IPO Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Zero2IPO Ventures?
The team at Zero2IPO Ventures includes Danny Chung (Managing Director), Gavin Ni (Founder,Chairman & CEO) and Hubert Yuan1 (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
